Zenosense, Inc. – Hospital Collaboration – 400 Person Lung Cancer Detection Trial

VALENCIA, SPAIN (Marketwired Dec 17, 2014) - Zenosense, Inc. (OTCQB: ZENO) ( Zenosense , the Company ), a healthcare technology company primarily focused on developing and marketing devices to detect the MRSA Super-Bug and to detect signs of lung cancer in exhaled breath, is pleased to announce that on 16 December 2014, the Company s development partner, Zenon Biosystem (Zenon) entered into a collaboration agreement for a lung cancer detection trial. The agreement is with a university and a large university hospital located in the region of Madrid, Spain. The trial will facilitate clinical tests on breath samples from 400 people, in line with the previously announced protocol design.  The Company is delighted that the university research scientists and the university hospital have all recognised the potential for our technology. A positive outcome may be a significant step toward a major healthcare breakthrough: Currently less than 20% of lung cancer is detected in the relatively t
http://bit.ly/1BYDZWQ